Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and SCRT in RAS-mutant rectal cancer liver metastases
NCT05640726Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in rectal cancer, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 36 months. Planned start May 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05640726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640726.